Pfizer Inc
-
{
- All
- News
- Videos
-
Pfizer Abandons Plan To Split Into Two
US drug maker Pfizer Inc said on Monday it had decided not to separate into two publicly traded companies by separating its low-growth generics from its patent-protected branded medicines.
-
Pfizer, Ranbaxy Win Dismissal of Lawsuit Over Generic Lipitor
US District Judge Peter Sheridan in Trenton, New Jersey, ruled that the plaintiffs, retailers and distribution companies that bought Lipitor directly from Pfizer, failed to plead their case with enough detail.
-
Pfizer Says Threats to Managers Force Staff Lockout at Mumbai Factory
The lockout at the Thane plant, which employs 212 people, would have no impact on the group's supply of medicines, a Pfizer Ltd spokesman said in a statement emailed to Reuters.
-
Pfizer Enters Takeover Discussions With AstraZeneca: Report
The renewed discussions suggest that the two sides might be getting closer to striking a friendly deal, but there is no guarantee the talks will go anywhere, the Journal said, adding that the terms of the informal offer from Pfizer couldn't be learned.
-
AstraZeneca Rejects Pfizer's Raised Bid of $106 Billion
US drugmaker Pfizer Inc raised its offer for AstraZeneca Plc to 63 billion pounds ($106 billion) on Friday, but the British company promptly rejected the proposal, which would create the world's biggest pharmaceuticals company.
-
Wall Street Edges Up Following Strong Jobs Report
US stocks edged higher on Friday following a payroll report that suggested a sharp rebound in economic activity early in the second quarter.
-
Pfizer Under Fire in Europe, US as it Weighs Next Astra Move
US drugmaker Pfizer is under fire on both sides of the Atlantic as it weighs its next move to buy British rival AstraZeneca, which could be a sweetened offer next week.
-
Pfizer chief says jobs will go in takeover
The US drugmaker has sought in writing to ease worries that British jobs will be lost and research undermined by the transaction - concerns that have made the takeover politically fraught. Critics on the committee, however, repeatedly attacked what they described as Pfizer's ruthless track record, accusing the company of buying foreign firms and th...
-
Pfizer-AstraZeneca Deal Not Quite Dead Yet
Morningstar analyst Damien Conover in Chicago said the odds of an AstraZeneca purchase had fallen well below the 50 per cent mark.
-
Pfizer gives up $117 billion pursuit of AstraZenaca
US drug major Pfizer today shelved its $117-billion takeover bid of AstraZenaca on the day of expiry of the offer as the British pharmaceutical company remained firm in opposing the deal.
-
Prices of More Essential Drugs May be Capped: Report
The committee will consider adding more drugs to the National List of Essential Medicines (NLEM), all of which would then come under price controls, one of the people told Reuters.
-
Pfizer chasing AstraZeneca in potential $100 billion deal
Pfizer said on Monday it made a 58.8 billion pounds ($98.9 billion) bid approach to AstraZeneca in January and had contacted its British rival again on April 26 seeking further discussions about a takeover.
-
Asia shares cautious before key events
Asian share markets crept cautiously higher on Tuesday after Wall Street notched up a late rally, but conviction was sorely lacking with Tokyo shut for a holiday and plenty of major events looming later in the week.
-
Stocks gain on merger speculation, crude oil falls
The Nasdaq composite index shed more than 1 per cent at one point as investors dumped growth shares regardless of companies' first-quarter results, but the tech-rich index recouped almost all losses by the market's close as investors piled into Apple Inc.
-
AstraZeneca India up on Pfizer offer for parent
AstraZeneca Pharma India shares have gained 53 per cent since January on speculation that its parent would be a takeover candidate.
-
Pfizer Abandons Plan To Split Into Two
US drug maker Pfizer Inc said on Monday it had decided not to separate into two publicly traded companies by separating its low-growth generics from its patent-protected branded medicines.
-
Pfizer, Ranbaxy Win Dismissal of Lawsuit Over Generic Lipitor
US District Judge Peter Sheridan in Trenton, New Jersey, ruled that the plaintiffs, retailers and distribution companies that bought Lipitor directly from Pfizer, failed to plead their case with enough detail.
-
Pfizer Says Threats to Managers Force Staff Lockout at Mumbai Factory
The lockout at the Thane plant, which employs 212 people, would have no impact on the group's supply of medicines, a Pfizer Ltd spokesman said in a statement emailed to Reuters.
-
Pfizer Enters Takeover Discussions With AstraZeneca: Report
The renewed discussions suggest that the two sides might be getting closer to striking a friendly deal, but there is no guarantee the talks will go anywhere, the Journal said, adding that the terms of the informal offer from Pfizer couldn't be learned.
-
AstraZeneca Rejects Pfizer's Raised Bid of $106 Billion
US drugmaker Pfizer Inc raised its offer for AstraZeneca Plc to 63 billion pounds ($106 billion) on Friday, but the British company promptly rejected the proposal, which would create the world's biggest pharmaceuticals company.
-
Wall Street Edges Up Following Strong Jobs Report
US stocks edged higher on Friday following a payroll report that suggested a sharp rebound in economic activity early in the second quarter.
-
Pfizer Under Fire in Europe, US as it Weighs Next Astra Move
US drugmaker Pfizer is under fire on both sides of the Atlantic as it weighs its next move to buy British rival AstraZeneca, which could be a sweetened offer next week.
-
Pfizer chief says jobs will go in takeover
The US drugmaker has sought in writing to ease worries that British jobs will be lost and research undermined by the transaction - concerns that have made the takeover politically fraught. Critics on the committee, however, repeatedly attacked what they described as Pfizer's ruthless track record, accusing the company of buying foreign firms and th...
-
Pfizer-AstraZeneca Deal Not Quite Dead Yet
Morningstar analyst Damien Conover in Chicago said the odds of an AstraZeneca purchase had fallen well below the 50 per cent mark.
-
Pfizer gives up $117 billion pursuit of AstraZenaca
US drug major Pfizer today shelved its $117-billion takeover bid of AstraZenaca on the day of expiry of the offer as the British pharmaceutical company remained firm in opposing the deal.
-
Prices of More Essential Drugs May be Capped: Report
The committee will consider adding more drugs to the National List of Essential Medicines (NLEM), all of which would then come under price controls, one of the people told Reuters.
-
Pfizer chasing AstraZeneca in potential $100 billion deal
Pfizer said on Monday it made a 58.8 billion pounds ($98.9 billion) bid approach to AstraZeneca in January and had contacted its British rival again on April 26 seeking further discussions about a takeover.
-
Asia shares cautious before key events
Asian share markets crept cautiously higher on Tuesday after Wall Street notched up a late rally, but conviction was sorely lacking with Tokyo shut for a holiday and plenty of major events looming later in the week.
-
Stocks gain on merger speculation, crude oil falls
The Nasdaq composite index shed more than 1 per cent at one point as investors dumped growth shares regardless of companies' first-quarter results, but the tech-rich index recouped almost all losses by the market's close as investors piled into Apple Inc.
-
AstraZeneca India up on Pfizer offer for parent
AstraZeneca Pharma India shares have gained 53 per cent since January on speculation that its parent would be a takeover candidate.
